Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum

Faraji, Azam; Akbarzadeh‐Jahromi, Mojgan; Bahrami, Shima; Gharamani, Sayeh; Shahraki, Hadi Raeisi; Kasraeian, Maryam; Vafaei, Homeira; Zare, Marjan; Asadi, Nasrin

doi:10.1080/01443615.2021.1955337

Cited by 12 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The remaining 12 studies were further scrutinized by reading the full text. Four studies were excluded, two of which only investigated first trimester levels of the markers, 26,27 and the other two studies had skewed data preventing acceptable estimation of the mean ± SD from the median (IQR) including one with a small sample size 28,29 . Finally, eight studies were included in this meta‐analysis 25,30–36 .…”

Section: Resultsmentioning

confidence: 99%

“…The study by Faraji et al was not included due to skewed data preventing accurate mean AE SD estimation from IQR. 29 They have reported significantly higher third-trimester PlGF levels among PAS cases when compared to controls, with no influence related to the type of PAS and proportion of concurrent placenta previa. However, they reported no significant difference in VEGF levels between both groups.…”

Section: Discussionmentioning

confidence: 96%

“…In the context of existing literature, inconsistencies regarding trends of VEGF and PlGF levels exists, even among studies that were not eligible for inclusion in our meta‐analyses. The study by Faraji et al was not included due to skewed data preventing accurate mean ± SD estimation from IQR 29 . They have reported significantly higher third‐trimester PlGF levels among PAS cases when compared to controls, with no influence related to the type of PAS and proportion of concurrent placenta previa.…”

Section: Discussionmentioning

confidence: 99%

“…Four studies were excluded, two of which only investigated first trimester levels of the markers, 26,27 and the other two studies had skewed data preventing acceptable estimation of the mean AE SD from the median (IQR) including one with a small sample size. 28,29 Finally, eight studies were included in this meta-analysis. 25,[30][31][32][33][34][35][36] All of them reported third trimester serum VEGF levels, 25,[30][31][32][33][34][35][36] while seven studies reported third trimester sFlt-1 levels, 25,[31][32][33][34][35][36] and only three studies explored PlGF levels.…”

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Association between placenta accreta spectrum and third‐trimester serum levels of vascular endothelial growth factor, placental growth factor, and soluble Fms‐like tyrosine kinase‐1: A meta‐analysis

Alzoubi

Maaita

Madain

et al. 2022

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim Antenatal suspicion of placenta accreta spectrum (PAS) currently relies on ultrasonographic findings, color doppler, and MRI, which have rendered it operator and expertise‐dependent. No serum markers for PAS have been integrated into clinical practice yet. The aim of this meta‐analysis was to identify potential serum markers for PAS by investigating third‐trimester serum levels of vascular endothelial growth factor (VEFG), placental growth factor (PIGF), and soluble Fms‐like tyrosine kinase‐1 (sFlt‐1) among PAS‐cases and controls. Methods PubMed, Scopus, EBSCO, Web of Science, and CNKI databases were systematically searched for relevant articles. Random‐effects model was applied to calculate the overall standardized mean difference (SMD) for each marker. Subgroup analysis and meta‐regression were performed to assess for potential covariates. Results Eight studies involving 366 PAS‐cases and 518 controls were included. Third trimester sFlt‐1 levels were significantly lower in PAS‐cases when compared to controls (SMD = −7.76, 95%CI = −10.42 to −5.10). This was, to a certain extent, consistent among studies though they differed in their extent of significance. Levels of VEGF (SMD = 1.59, 95%CI = −0.07 to 3.25) and PlGF (SMD = −0.49, 95%CI = −1.66 to 0.67) were not significantly different between PAS cases and controls, in which studies demonstrated conflicting results. Conclusions Third trimester sFlt‐1 levels may be useful to predict PAS. Nonetheless, further studies are recommended to better understand conflicting results before adopting either VEGF or PlGF.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Association between placenta accreta spectrum and third‐trimester serum levels of vascular endothelial growth factor, placental growth factor, and soluble Fms‐like tyrosine kinase‐1: A meta‐analysis

Alzoubi

Maaita

Madain

et al. 2022

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Serum VEGF was able to predict the need for peripartum hysterectomy by plotting RUC curves (AUC = 0.698, 95% CI 0.564–0.832, LR+2.4, LR−0.3, p = 0.004). This phenomenon provides a clear advantage for clinical application ( 16 – 18 ). However, due to the study's sample sizes and limited relevant reports, these remain controversial conclusions.…”

Section: Biomarkersmentioning

confidence: 99%

Potential Serum Biomarkers in Prenatal Diagnosis of Placenta Accreta Spectrum

Zhang

2022

Front. Med.

View full text Add to dashboard Cite

Placenta accreta spectrum (PAS) refers to the abnormal invasion of trophoblastic tissues. Because of its increasing morbidity and possibility of catastrophic outcomes, PAS requires an antenatal diagnosis and making full preparations in advance to realize safe delivery. Current clinical screening modalities for PAS are not always conclusive. Recently, it has been reported that bio-markers detected in maternal serum have the potential for predicting PAS during pregnancy. Some of these biomarkers, such as β-hcg, AFP, PAPP-A, and cffDNA, can be clinically detected. It is convenient for us to test and compare with standard threshold. However, how can we distinguishing PAS from other pregnancy complications through these biomarkers remains complicated. Some biomarkers are specific, such as microRNA and placenta-specific mRNA. They are stability and reliability. These biomarkers are currently research hotspots. This study aims to summarize the characteristics of the newly reported biomarkers and to point out their potential application and current limitations to provide a basis for future research. Finally, the combination of imageological examination and biomarkers will be an attractive future theme to study in diagnosing this challenging condition.

show abstract

Assessment of serum levels and placental bed tissue expression of IGF-1, bFGF, and PLGF in patients with placenta previa complicated with placenta accreta spectrum disorders

Arakaza,

Liu,

Zhu

et al. 2024

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum

Cited by 12 publications

References 31 publications

Association between placenta accreta spectrum and third‐trimester serum levels of vascular endothelial growth factor, placental growth factor, and soluble Fms‐like tyrosine kinase‐1: A meta‐analysis

Association between placenta accreta spectrum and third‐trimester serum levels of vascular endothelial growth factor, placental growth factor, and soluble Fms‐like tyrosine kinase‐1: A meta‐analysis

Potential Serum Biomarkers in Prenatal Diagnosis of Placenta Accreta Spectrum

Assessment of serum levels and placental bed tissue expression of IGF-1, bFGF, and PLGF in patients with placenta previa complicated with placenta accreta spectrum disorders

Contact Info

Product

Resources

About